A Safety and Efficacy Study of Farletuzumab in Participants With Adenocarcinoma of the Lung
Status:
Completed
Trial end date:
2013-11-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to compare the effect of farletuzumab versus placebo
in combination with either a platinum agent (carboplatin) with paclitaxel or a platinum agent
(carboplatin or cisplatin) with pemetrexed followed by farletuzumab or placebo on
investigator-assessed progression free survival (PFS) as determined by Response Evaluation
Criteria in Solid Tumors (RECIST) v.1.1 or definitive clinical disease progression (eg, new
occurrence of positive fluid cytology) in chemotherapy naive participants with folate
receptoralpha (FRA)-expressing Stage IV adenocarcinoma of the lung.